Clinical and genetic data of U.S. citizens obtained by Chinese biotechnology companies through their partnerships with U.S. institutions could pose national security risks, according to a newly published congressional report.
The risks stem from the “dual use of biotechnology information,” the U.S.–China Economic and Security Review Commission (USCC) said in a report published Feb. 14. For instance, genetic and medical analyses used in the biotech industry to develop tailored treatments for patients “could be used for malicious purposes in the hands of a foreign state government, such as China.”
